Asthma Clinical Trial
— PopDataOfficial title:
The Economic Burden of Asthma in Canada
| Verified date | August 2017 |
| Source | University of British Columbia |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
The study will consist of three phases: Phase A: General population survey for estimation of the prevalence of asthma, and prospective collection of resource utilization and quality-of-life data for 12 months, Phase B: comparison of healthcare resource usage collected prospectively to the data collected using administrative data in the population recruited in Phase A, and Phase C: Economic modeling of asthma to extrapolate the findings across Canada and into the future years.
| Status | Completed |
| Enrollment | 613 |
| Est. completion date | June 2017 |
| Est. primary completion date | September 2013 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 1 Year to 85 Years |
| Eligibility |
Inclusion Criteria: 1. Patient must state that they have had a diagnosis of asthma by a physician. In addition, the patient must have had a self-reported health care interaction related to asthma (physician visit, ED visit, hospitalization) in the past 5 years. 2. Patient must be 1 to 85 years old. Exclusion Criteria: 1. Patients unable to provide informed consent due to language difficulties or cognitive impairment. 2. Patients who have a greater than 10 pack-year smoking history (this will exclude patients with possible COPD). 3. Patients who know that they will be moving out of the province within 12 months of study entry. 4. Patients in whom metacholine challenge test is contraindicated due to non-asthma-related reasons (e.g. patients with cerebral aneurysm, pregnant and breastfeeding participants). |
| Country | Name | City | State |
|---|---|---|---|
| n/a | |||
| Lead Sponsor | Collaborator |
|---|---|
| University of British Columbia | GlaxoSmithKline |
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Costs of asthma in BC and Canada per patient | Costs per patients will be calculated by multiplying the amount of healthcare resources used by the corresponding unit costs. The investigators will adjust all unit costs to 2010 Canadian dollar according to the medical care component of the Consumer Price Index(42). The lowest price for available (generic drugs if exists) versions of medications will be used based on province-specific data. | September 2013 | |
| Secondary | Calculating quality of life of participants with asthma using the Asthma Quality of Life Questionnaire | The investigator will report mean from the Asthma Quality of Life Questionnaire (Pediatric Asthma Quality of Life Questionnaire in children) for each participant. The mean Asthma Quality of Life Questionnaire score for baseline and each follow-up visit among all participants will also be calculated. The investigator will use a linear mixed model (with a random effect parameter for each participant) to calculate the rate of change in Asthma Quality of Life Questionnaire over the study period. | January 2017 | |
| Secondary | Calculating quality of life of participants with asthma using the EuroQol's EQ-5D Questionnaire | The investigator will report mean from the EuroQol's EQ-5D data. Based on the available EuroQol's EQ-5D responses for each participant, the investigator will calculate the Quality Adjusted Life Years for each participant, assuming linear change in EuroQol's EQ-5D scores between successive measurements. | February 2017 |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
| Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
| Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
| Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
| Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
| Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
| Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
| Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
| Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
| Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
| Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
| Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
| Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
| Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
| Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
| Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
| Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
| Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
| Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
| Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|